Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7617991 in MAGE-A4+ Solid Tumors
NCT06372574Phase 1Withdrawn
- Sponsor
- Genentech
- Start
- Sep 2024
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, T-cell Engagers, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of RO7617991 in solid tumor, sponsored by Genentech. Primary endpoints: Incidence and Severity of Adverse Events, Number of Participants with Abnormal Values in Targeted Vital Signs and 1 more. Planned start Sep 2024; status: withdrawn.
02
Drugs
RO7617991
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06372574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372574.